# Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

> **NCT01818986** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Metastatic Castrate-resistant Prostate Cancer
- mCRPC

## Interventions

- **DRUG:** Sipuleucel-T
- **RADIATION:** Stereotactic Ablative Body Radiation

## Key facts

- **NCT ID:** NCT01818986
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-10
- **Primary completion:** 2019-12-20
- **Final completion:** 2021-05-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818986, "Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01818986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*